New data from Janssen presented at the Annual European Congress of Rheumatology (EULAR 2019) shows sustained clinical benefit and reduction in severe flares with Stelara® (ustekinumab) in patients with systemic lupus erythematosus (SLE)

133

MADRID–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson presented this week results of two analyses from a Phase 2 study of Stelara®* (ustekinumab) in systemic lupus erythematosus (SLE). The studies highlight not only the sustained clinical benefit of ustekinumab – an anti-interleukin (IL) IL-12/23 p40 neutralising monoclonal antibody – on SLE disease activity at one-year, but also show a reduction in the rate of severe flares. They also provide new insights into …

 

http://www.businesswire.com/news/home/20190613005277/en/New-data-Janssen-presented-Annual-European-Congress/